Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Quarterly Report · 10-Q

Avita Medical, Inc.

Quarterly Report

Filed Aug 6, 2026Accepted Aug 6, 2026, 4:20 PM EDTCIK 1762303Accession 0001193125-26-338101
Share

Company context

AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx®, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix.

Current securities

Recent company filings

  1. S-8 filingAug 25, 2026
  2. 4/A filingAug 24, 2026
  3. Entry into a Material Definitive AgreementAug 11, 2026
  4. Submission of Matters to a Vote of Security HoldersAug 6, 2026
  5. Results of Operations and Financial ConditionAug 6, 2026

As-filed source

Primary evidence